Intech Investment Management LLC lowered its stake in West Pharmaceutical Services, Inc. (NYSE:WST – Free Report) by 30.4% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 5,248 shares of the medical instruments supplier’s stock after selling 2,295 shares during the period. Intech Investment Management LLC’s holdings in West Pharmaceutical Services were worth $1,444,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently added to or reduced their stakes in the stock. Geode Capital Management LLC boosted its position in West Pharmaceutical Services by 0.6% in the fourth quarter. Geode Capital Management LLC now owns 1,869,086 shares of the medical instruments supplier’s stock valued at $512,250,000 after buying an additional 11,962 shares in the last quarter. Employees Retirement System of Texas boosted its position in West Pharmaceutical Services by 6.3% in the fourth quarter. Employees Retirement System of Texas now owns 12,966 shares of the medical instruments supplier’s stock valued at $3,567,000 after buying an additional 766 shares in the last quarter. Roundview Capital LLC boosted its position in West Pharmaceutical Services by 385.8% in the fourth quarter. Roundview Capital LLC now owns 3,804 shares of the medical instruments supplier’s stock valued at $1,047,000 after buying an additional 3,021 shares in the last quarter. Allstate Corp boosted its position in West Pharmaceutical Services by 104.8% in the fourth quarter. Allstate Corp now owns 5,265 shares of the medical instruments supplier’s stock valued at $1,449,000 after buying an additional 2,694 shares in the last quarter. Finally, Clearstead Advisors LLC boosted its position in West Pharmaceutical Services by 12.7% in the fourth quarter. Clearstead Advisors LLC now owns 3,751 shares of the medical instruments supplier’s stock valued at $1,032,000 after buying an additional 422 shares in the last quarter. Institutional investors and hedge funds own 93.90% of the company’s stock.
Insiders Place Their Bets
In related news, CAO Chad Winters sold 896 shares of West Pharmaceutical Services stock in a transaction on Monday, April 27th. The shares were sold at an average price of $300.67, for a total transaction of $269,400.32. Following the completion of the transaction, the chief accounting officer owned 1,523 shares of the company’s stock, valued at $457,920.41. This trade represents a 37.04% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Annette F. Favorite sold 2,817 shares of West Pharmaceutical Services stock in a transaction on Monday, April 27th. The stock was sold at an average price of $305.20, for a total transaction of $859,748.40. Following the transaction, the vice president directly owned 16,828 shares of the company’s stock, valued at $5,135,905.60. This represents a 14.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.60% of the stock is owned by company insiders.
Analysts Set New Price Targets
Check Out Our Latest Stock Analysis on WST
West Pharmaceutical Services Price Performance
Shares of NYSE:WST opened at $314.64 on Friday. West Pharmaceutical Services, Inc. has a 52 week low of $206.80 and a 52 week high of $330.88. The firm’s fifty day moving average is $290.87 and its 200-day moving average is $269.27. The firm has a market cap of $22.23 billion, a PE ratio of 42.06, a price-to-earnings-growth ratio of 2.66 and a beta of 1.18. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.04 and a current ratio of 2.71.
West Pharmaceutical Services (NYSE:WST – Get Free Report) last announced its earnings results on Thursday, April 23rd. The medical instruments supplier reported $2.13 earnings per share for the quarter, topping analysts’ consensus estimates of $1.68 by $0.45. West Pharmaceutical Services had a net margin of 16.85% and a return on equity of 19.03%. The business had revenue of $844.90 million during the quarter, compared to the consensus estimate of $779.68 million. During the same quarter last year, the firm earned $1.45 earnings per share. West Pharmaceutical Services’s quarterly revenue was up 21.0% on a year-over-year basis. West Pharmaceutical Services has set its FY 2026 guidance at 8.400-8.750 EPS and its Q2 2026 guidance at 2.050-2.120 EPS. Sell-side analysts predict that West Pharmaceutical Services, Inc. will post 8.6 earnings per share for the current year.
West Pharmaceutical Services declared that its Board of Directors has authorized a share repurchase program on Tuesday, February 17th that permits the company to buyback $1.00 billion in shares. This buyback authorization permits the medical instruments supplier to buy up to 5.6% of its shares through open market purchases. Shares buyback programs are typically a sign that the company’s leadership believes its shares are undervalued.
West Pharmaceutical Services Profile
West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.
In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.
Featured Stories
- Five stocks we like better than West Pharmaceutical Services
- AI Server Earnings: Wall Street Sees One Clear Standout
- Navitas: NVIDIA’s AI Power Broker?
- A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below
- NVIDIA’s New Power Play: Why Fluence Is Surging
Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. (NYSE:WST – Free Report).
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.
